Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Pulmonx (LUNG) has 7 years of Free Cash Flow data on file, last reported at -$7.9 million in Q3 2025.

• On a quarterly basis, Free Cash Flow fell 24.08% year-over-year to -$7.9 million in Q3 2025; TTM through Dec 2025 was -$25.3 million, a 20.29% increase from a year earlier, with the FY2024 full-year figure at -$31.8 million, up 15.81% from the prior year.
• Free Cash Flow for Q3 2025 stood at -$7.9 million, down from -$4.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for LUNG reached as high as -$4.0 million in Q2 2025 and fell as low as -$15.6 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$9.8 million across 5 years, with a median of -$9.1 million in 2022.
• Across the five-year window, Free Cash Flow tumbled 81.52% in 2021 and surged 40.21% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$14.3 million in 2021, then soared by 36.56% to -$9.1 million in 2022, then increased by 6.47% to -$8.5 million in 2023, then rose by 18.76% to -$6.9 million in 2024, then slipped by 13.71% to -$7.9 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$7.9 million in Q3 2025, -$4.0 million in Q2 2025, and -$13.5 million in Q1 2025.